Sun Pharma Announces the Availability of UNLOXCYT^™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

Sun Pharmaceutical Industries Limited announced UNLOXCYT™ (cosibelimab-ipdl) is now available in the US for healthcare professionals to prescribe for adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation.